All Oncology News

177Lu-PSMA-I&T improved radiographic progression-free survival vs hormonal therapy in PSMA-positive metastatic castration-resistant prostate cancer.

A retrospective study showed pacritinib improved symptoms in transfusion-dependent myelofibrosis.

SELECT-MDS-1 will be discontinued after failing to meet its primary end point of improved CR rates with tamibarotene/azacitidine in high-risk, RARA+ MDS.

Health Canada has approved momelotinib for the treatment of splenomegaly and/or disease-related symptoms in myelofibrosis with moderate-to-severe anemia.

First-line zanubrutinib generated a longer PFS in treatment-naive chronic lymphocytic leukemia/small lymphocytic lymphoma vs relapsed/refractory disease.

Fox Chase Cancer Center’s Dr. Vanessa Wookey Presents Rectal Cancer Research at 24th Annual ECOG-ACRIN Young Investigator Symposium

IBI354 showed favorable safety and efficacy in patients with advanced HER2-positive and HER2-low breast cancer.

AstraZeneca has filed a new BLA for Dato-DXd in pretreated, EGFR-mutated advanced non–small cell lung cancer.

The FDA has awarded rare pediatric disease designation to the novel GSK-3β inhibitor elraglusib for the treatment of Ewing sarcoma.

The institute builds upon institutional expertise to develop and advance impactful cell therapies for cancer, autoimmune conditions and infections.

Revumenib met the CR/CRh primary end point of the phase 2 AUGMENT-101 trial in NPM1-mutated acute myeloid leukemia.

Pimicotinib improved responses compared with placebo in tenosynovial giant cell tumor.

Selumetinib led to a statistically significant and clinically meaningful improvement in ORR compared with placebo in adult patients with neurofibromatosis.

Kathleen N. Moore, MD, MS, discusses the evolving treatment landscape of platinum-resistant ovarian cancer.

Zolbetuximab plus chemotherapy extended PFS and OS in HER2–, locally advanced unresectable or metastatic, CLDN18.2+ gastric/GEJ adenocarcinoma.

Kari Wisinski, MD, highlights treatments for HER2– breast cancer, the role of chemotherapy in TNBC, and the benefits of T-DXd for brain metastases.

RP1 plus nivolumab generated responses in advanced melanoma that progressed on or after prior anti–PD-1 therapy.

The investigational PRAME-targeted T-cell therapy IMA203 generated responses in melanoma and other solid tumors,

Phase 1 data showed the potential for invikafusp alfa as a precision cancer immunotherapeutic agent in solid tumors after exposure to PD-(L)1 therapy.

Patients with newly diagnosed glioblastoma had improved survival when treated with TTFields plus temozolomide and pembrolizumab.

E-602 plus cemiplimab elicited preliminary antitumor activity and had a tolerable safety profile in PD-(L)1–resistant solid tumors.

Administration of fixed-dose CAR T cells followed by escalating doses of UB-TT170 led to changes in cytokine levels in relapsed/refractory osteosarcoma.

Early cytokine induction after CAR T-cell therapy infusion predicts CAR expansion in patients with leukemia or lymphoma treated with axi-cel or brexu-cel.

UCSF Life Sciences Building will bring research, innovation, specialty care clinics, and world-class cancer therapy to San Francisco’s central waterfront.

Debra L. Richardson, MD, FACS, FACOG, discusses how selinexor may address the need for effective maintenance therapies in pMMR, TP53 wild-type endometrial cancer.

Investigators who champion patient-partnered cancer research have experienced challenges to their effective implementation.

Janaki Neela Sharma, MD, discusses takeaways from the Sylvester Comprehensive Cancer Center 2024 Annual Oncology Update.

Obe-cel wins FDA approval in relapsed/refractory B-cell ALL, FDA approval is sought for sunvozertinib in EGFR exon 20–positive NSCLC, and more.

David A. Braun, MD, PhD, discusses the potential for protein glycosylation as a biomarker to predict nivolumab/cabozantinib responses in advanced RCC.

The FDA has approved obecabtagene autoleucel for relapsed/ refractory B-cell precursor acute lymphoblastic leukemia.